Efficacy Study of Dysport® in the Treatment of Anal Fissure.
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
To evaluate the effect on healing rates of two different prognostic factors in patients
 treated with Dysport® for anal fissure: duration of fissure and dose of study drug
Inclusion Criteria:

 -  Patients having idiopathic anal fissure in the posterior anal midline

 -  Patients having anal fissure present for less than 6 months

 -  Patients having symptoms (pain) present for a minimum of 2 weeks and not responding
 after 2 weeks of standard therapy (diet, laxatives, sitz-bathes)

 Exclusion Criteria:

 -  Patients having anal fistulas or anal fissure of various causes such as Crohn disease,
 Behcet infectious ulceration, anal suppuration, subfissural infiltration, abscesses,
 acute haemorrhoidal attacks or inflammatory bowel disease

 -  Patients having idiopathic anal fissure in the anterior anal midline

 -  Patients having lateral or multiple fissures

 -  Patients having anal or perianal cancer

 -  Patients who underwent previous anal surgery or have cicatricial alterations or
 post-surgical cicatricial lesions

 -  Patients receiving drugs affecting neuromuscular transmission

 -  Patients who have received topical anaesthetic within 3 days of injection

 -  Patients receiving local treatment by myorelaxing agent

 -  Patients receiving prohibited analgesics

 -  Patients having bleeding disturbances or currently using coumarin derivates

 -  Patients having myasthenia or any genetic muscle disease